CPSC Recall in 2020: GSK Consumer Health Recalls Five Excedrin Brands Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning

Updated on March 25, 2026.

See the recall details below. You can also see similar information for other consumer product recalls in 2020.

Data Source: CPSC.

Recall Number: 21-057

Date: December 23, 2020

Product Name: Excedrin Migraine Caplets, Excedrin Migraine Geltabs, Excedrin Extra Strength Caplets, Excedrin PM Headache Caplets, and Excedrin Tension Headache Caplets

Recall Description:

This recall involves 50, 80, 100, 125, 200, 250 and 300-count bottles of Excedrin Migraine Caplets, Excedrin Migraine Geltabs, Excedrin Extra Strength Caplets, Excedrin PM Headache Caplets, and Excedrin Tension Headache Caplets.  The bottles are plastic with a child-resistant closure.  For a full list of the recalled products, visit www.excedrin.com/products/discontinued.

Hazard Description:

Some of the bottles containing the over-the-counter drug can have a hole in the bottom.  If there is a hole, children could access and swallow the contents, posing a risk of poisoning.  These products contain the substances aspirin and acetaminophen which must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA).

Consumer Action:

Remedy Type:

Refund

Units: About 433,600

Incidents:

None reported.

Sold At:

Pharmacies, department stores, grocery stores, and hypermarkets nationwide and online from March 2018 through September 2020 for between $7 and $18.

Manufactured In:

United States